Blake Borgeson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 220,000 shares at $4.20 ($924K) on 2026-02-03, disclosed to the SEC on 2026-02-06.
Scheduled sale ($924k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RXRX | SELL | 2026-08-06 | $98K | — | Filing → |
| RXRX | SELL | 2026-07-09 | $159K | — | Filing → |
| RXRX | SELL | 2026-06-04 | $110K | — | Filing → |